BioCardia, Inc. (BCDA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript
BioCardia, Inc. (NASDAQ:BCDA ) Q2 2025 Earnings Conference Call August 11, 2025 7:00 AM ET Company Participants David McClung - Chief Financial Officer Miranda Peto Benvenuti - Corporate Participant Peter A. Altman - CEO, President & Director Conference Call Participants James Francis Molloy - Alliance Global Partners, Research Division Kumaraguru Raja - Brookline Capital Markets, LLC, Research Division Lander Egaña-Gorroño - H.C.
BioCardia, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Amy Taylor Pingora Partners LLC | 35,739 | $45,147.46 | $31,450.32 | -$13,697.14 | -30.34% |
BioCardia, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JP Joseph Pantginis HC Wainwright & Co. | 413,676.05 | $355,761.41 | $364,034.93 | $8,273.52 | 2.33% |
BioCardia, Inc. (BCDA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioCardia, Inc. ever had a stock split?
BioCardia, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Peter A. Altman CEO | NASDAQ (CM) Exchange | 09060U507 CUSIP |
| US Country | 17 Employees | 6 Jun 2019 Last Dividend | 6 Jun 2019 Last Split | 14 Mar 2008 IPO Date |
Overview
BioCardia, Inc. is a clinical-stage company focused on the development of regenerative medicine and therapeutics aimed at treating cardiovascular and pulmonary diseases. With its base of operations in Sunnyvale, California, BioCardia is advancing the field through its innovative approach in cell and cell-derived therapy research. The company's efforts are centered on addressing heart failure, chronic myocardial ischemia, and other cardiac and pulmonary conditions through pioneering treatments designed to improve patient outcomes and quality of life.
Products and Services
- CardiAMP Cell Therapy System
- Allogeneic Cell Therapy
- Helix Biotherapeutic Delivery System
- Morph Deflectable Guides and Sheaths
This system represents BioCardia's lead therapeutic innovation, targeting heart failure and chronic myocardial ischemia through autologous mononuclear cell therapy. It showcases a personalized approach to treatment, utilizing the patient's own cells in an effort to regenerate damaged heart tissue and improve cardiac function.
BioCardia is also developing allogeneic cell therapies for both cardiac and pulmonary diseases. This involves using cells from donors rather than the patients themselves, offering a potential off-the-shelf solution for various conditions. One key example is the investigational culture expanded bone marrow derived mesenchymal cell therapy, currently in Phase I/II trial for ischemic heart failure.
The Helix system signifies a novel approach to deliver therapeutics directly into the heart muscle. This minimally invasive tool employs a penetrating helical needle designed for precise delivery from within the heart, optimizing the efficacy of treatments.
Complementing its therapeutic offerings, BioCardia provides Morph deflectable guides and sheaths. These are innovative devices designed to enhance the delivery of therapeutics by offering improved navigability and access to challenging anatomical heart regions during procedures.
